Investing in biotech stocks requires more than just financial know-how; one has understand a bit of the science behind the companies and products.

Biotech companies issue press releases all the time touting the potential of their experimental drugs, and the stocks move as a result.

But how do you separate the truth from the hype? What sort of questions should you be asking yourself when you evaluate these press releases? And where can you find the unbiased information you need?

Adam Feuerstein offers valuable insights in interpreting press releases, taking Point Therapeutics' press release as a case in point.